Bookmark and Share

Bernard A Fischer IV
 

Bernard A Fischer IV M.D., M.A.

Academic Title: Assistant Professor
Primary Appointment: Psychiatry
bfischer@mprc.umaryland.edu
Location: Maryland Psychiatric Research Center, PO Box 21247
Phone: (410) 402-7548
Fax: (410) 402-7198

Personal History:

Dr. Fischer was born and raised in Baltimore. He graduated magna cum laude with a degree in psychology from the University of Maryland Baltimore County (UMBC). He received a master's degree in healthcare ethics from the University of Maryland prior to attending medical school at the Medical College of Virginia. Dr. Fischer completed residency training in psychiatry at the University of Maryland/Sheppard Pratt. Following residency, he completed an NIH-funded research fellowship at the Maryland Psychiatric Research Center. He is a fellow of the American Psychiatric Association and board certified in psychiatry (ABPN Number 57114) and addiction medicine (ABAM Number 2010163). Dr. Fischer is also a Lieutenant Commander in the Medical Corps of the United States Navy Reserve.

Research Interests:

Dr. Fischer's research interests center on schizophrenia. He has a special interest in developing psychopharmacological treatments for the unmet therapeutic needs of the illness: specifically co-occurring substance use disorders, negative symptoms, and cognition. Dr. Fischer also has a long-standing interest in research ethics.

Clinical Speciality:

Dr. Fischer has clinical expertise in treatment of psychotic disorders: therapy (group, family, individual) and psychopharmacology (including expertise prescribing clozapine).


Publications:

Selected Peer Reviewed Articles:

Fischer IV BA. A summary of important documents in the field of research ethics. Schizophr Bull 2006; 32 (1), 69-80. (PMID: 16192409; PMCID: PMC2632196).

Kirkpatrick B, Fischer B. Subdomains within the negative symptoms of schizophrenia: Commentary. Schizophr Bull 2006; 32 (2): 246-9. (PMID: 16492798).

Sandson NB, Cozza KL, Armstrong SC, Eckermann G, Fischer BA, Phillips B. Med-Psych Drug-Drug Interactions Update: Clozapine Case Series. Psychosomatics 2007; 48:170-5. (PMID: 17329613).

Fischer BA, Weiner E. Clozapine levels lowered by modafinil: A case report and brief review of modafinil in schizophrenia. Clin Schizophr Relat Psychoses 2008; 2(1): 88-90.

Bhanji NH, Baron DA, Lacy BW, Gross LS, Goin MK, Sumner CR, Fischer BA, Slaby AE. Direct-to-consumer marketing: An attitude survey of psychiatric physicians. Primary Psychiatry 2008; 15(11):67-71.

Fischer BA, Carpenter Jr WT. Will the Kraepelinian dichotomy survive DSM-V? Neuropsychopharmacology 2009; 34(9):2081-7. (PMID: 19295511).

Buchanan RW, Kreyenbuhl J, Kelly D, Noel J, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophr Bull 2010; 36(1):71-93. (PMID: 19955390; PMCID: PMC2800144).

Fischer BA, Boggs DL. The role of antihistaminic effects in the misuse of quetiapine: A case report and review of the literature. Neurosci Biobehav Rev 2010; 34(4):555-8. (PMID: 19896973).

Fischer BA, George P. The investigator and the IRB: A survey of depression and schizophrenia researchers. Schizophr Res 2010, 122(1-3):206-212. (PMID: 20064703; PMCID: PMC2895950).

Kirkpatrick B, Strauss G, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR. The Brief Negative Symptom Scale: Psychometric properties. Schizophr Bull 2011; 37(2):300-5. (PMID: 20558531; PMCID: PMC3044634).

Keller WR, Fischer BA, Carpenter WT. Revisiting the diagnosis of schizophrenia: Where have we been and where are we going? CNS Neurosci Ther 2011; 17(2):83-8. (PMID: 21199450).

Fischer BA, Keller WR, Arango C, Pearlson G, McMahon RP, Meyer WA, Francis A, Kirkpatrick B, Carpenter WT, Buchanan RW. Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophr Res 2012; 136(1-3):51-4. (PMID: 22336954; PMCID: PMC3298625).

Fischer, BA. Maltreatment of people with serious mental illness in the early Twentieth Century: A focus on Nazi Germany and eugenics in America. J Nerv Ment Dis 2012; 200(12):1096-1100. (PMID: 23197125).

Krishna N, Chiappelli J, Fischer BA, Knight S. Tacrolimus-induced paranoid delusions and fugue-like state. Gen Hosp Psychiatry; Epublished ahead of print, doi: 10.1016/j.genhosppsych.2012.07.010. (PMID: 22959421).

Strauss GP, Hong LE, Keller WR, Buchanan RW, Gold JM, Fischer BA, McMahon RP, Catalano LT, Culbreth AJ, Carpenter WT, Kirkpatrick B. Factor Structure of the Brief Negative Symptom Scale. Schizophr Res 2012; 142(1-3):96-8. (PMID: 23062750; PMCID: PMC3502636).

Fischer BA. A review of American psychiatry through its diagnoses: The history and development of the Diagnostic and Statistical Manual of Mental Disorders. J Nerv Ment Dis 2012; 200 (12):1022-30. (PMID: 23197117).

Strauss GP, Keller WR, Buchanan RW, Gold JM, Fischer BA, McMahon RP, Catalano LT, Culbreth AJ, Carpenter WT, Kirkpatrick B. Next-Generation Negative Symptom Assessment for Clinical Trials: Validation of the Brief Negative Symptom Scale. Schizophr Res 2012; 142(1-3):88-92. (PMID: 23127378; PMCID: PMC3502630).

Krishna N, Patchan K, Register-Brown K, Fischer BA, Hackman A. The Role of social media networks in psychotic disorders: A case report. Gen Hosp Psychiatry; Epublished ahead of print, doi: 10.1016/j.genhosppsych.2012.10.006. (PMID: 23174460).

Strauss GP, Horan WP, Kirkpatrick B, Fischer BA, Keller WR, Miski P, Buchanan RW, Green MF, Carpenter WT. Deconstructing negative symptoms of schizophrenia: Avolition-apathy and emotional expression clusters predict clinical presentation and functional outcome. J Psychiatric Res 2013; 47(6):783-90. (PMID: 23453820).

Vidal C, Reese C, Fischer BA, Chiapelli J, Himelhoch S. Meta-analysis of efficacy of mirtazapine as an adjunctive treatment for negative symptoms in schizophrenia. Clin Schizophr Relat Psychoses; Epublished ahead of print. (PMID: 23491969).

Fischer BA, McMahon RP, Meyer WA, Slack DJ, Appelbaum PS, Carpenter WT Jr. Participants with schizophrenia retain the information necessary for informed consent during clinical trials. J Clin Psychiatry 2013; 74(6):622-7. (PMID: 23842013).

Fischer, BA. The unofficial myths of schizophrenia. [Invited editorial]. J Nerv Ment Dis 2012; 200(7):567-8. (PMID: 22759931).

Keller WR, Vidal C, Park ES, Strauss GP, Fischer BA. The risk of diabetes in deficit schizophrenia. Clin Schizophr Relat Psychoses; Epublished ahead of print. (PMID: 23491970).

Keller WR, Fischer BA, McMahon RP, Meyer W, Buchanan RW. Open-label salsalate for the treatment of pre-diabetes in people with schizophrenia. Schizophr Res; Epublished ahead of print. (PMID: 23680037).

Book Chapters:

Fischer, IV, B.A. & Carpenter, Jr., W.T. Remission, in The Clinical Handbook of Schizophrenia, Editors: Mueser, K. T. & Jeste, D.V., Guilford Publications, Inc., NY, 2008, pp. 559-65.

Fischer, IV, B.A., Kirkpatrick, B., Carpenter, Jr., W.T. The Neurobiology of Negative Symptoms and The Deficit Syndrome, in The Handbook of Neurochemistry and Molecular Neurobiology, Editor: Lajtha, A., 3rd edition; Volume 27: Schizophrenia, Volume Editors: Javitt, D.C. & Kantrowitz J.T., Springer Science and Business Media LLC, 2009, pp. 507-23.

Fischer, BA & Buchanan, RW. Schizophrenia: Clinical Manifestations, Assessment, Diagnosis, and Course. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2013.

Fischer, BA & Buchanan, RW. Schizophrenia: Epidemiology and Pathogenesis. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2013.